title: Thromboembolism and pancreatic cancer.
abstract: Venous thromboembolism (VTE) is a frequent event in the clinical course of patients with exocrine pancreatic cancer; studies have been designed to evaluate the role of prophylactic anticoagulation in this ominous disease. Searching for the molecular basis of thrombosis in cancer, Bozkurt et al. present in the Abstract #e22049 the result of their investigation on the frequency of inherited and carcinogenesis-acquired proteins in oncologic patients with and without venous thromboembolism. From the bedside, Muñoz Martin et al. present in the Abstract #e15187 their work on the incidence of venous thromboembolism in patients with exocrine pancreatic cancer and the role of the established Khorana score in predicting symptomatic and incidental venous thromboembolism. At last, Cella et al. in the Abstract #e20625 expand the predictor landscape from the Khorana score to other risk factors for venous thromboembolism, refining the selection of oncologic patients who can benefit from prophylactic anticoagulation.
authors: Department of Hematology and Oncology, Tufts Medical Center. Boston, MA, USA. andrelpbs@mwmc.org.
authors: Andre Luiz
authors: AL
authors: De Souza
authors: Muhammad Wasif
authors: MW
authors: Saif
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D017063:Outcome Assessment, Health Care; D010190:Pancreatic Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D011110:Polymorphism, Genetic; D018570:Risk Assessment; D012307:Risk Factors; D013923:Thromboembolism / Q000150:complications* / Q000188:drug therapy / Q000235:genetics
chemical_list: D000925:Anticoagulants